Lab
Weland Clinical Laboratories, P.C.
Weland Clinical Laboratories, P.C. was paid $3.82M by Medicaid between Jan 2018 and Dec 2024, across 102 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 32% of everything it billed.
33Billing provider infoWELAND CLINICAL LABORATORIES, P.C.
CEDAR RAPIDS, IA 52402
CEDAR RAPIDS, IA 52402
33aNPI1235121450assigned 08/16/2005
33bProvider typeClinical Medical Laboratory
28Total paid$3.82M
24GClaims209,987
24DCodes billed102
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Iowa
Rank by total paid#4 of 35
Median peer was paid$42K
This provider vs. median92×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,805 | $506K | |
| 2019 | 32,203 | $543K | |
| 2020 | 26,578 | $509K | |
| 2021 | 28,199 | $580K | |
| 2022 | 29,132 | $588K | |
| 2023 | 30,542 | $603K | |
| 2024incomplete | 28,528 | $489K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 32% | 18,754 | 16,679 | $1.23M |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 6.7% | 11,712 | 11,398 | $255K |
| 88307 | 6.4% | 3,344 | 3,144 | $243K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 5.2% | 6,618 | 6,416 | $198K |
| 80050 | General health panel | 3.8% | 3,325 | 3,057 | $144K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.7% | 2,780 | 1,482 | $142K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.5% | 2,765 | 2,658 | $94K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.5% | 2,760 | 2,653 | $94K |
| 88342 | 2.0% | 2,118 | 1,871 | $77K | |
| 87660 | 2.0% | 4,129 | 3,851 | $77K | |
| 87480 | 2.0% | 4,127 | 3,842 | $77K | |
| 87510 | 2.0% | 4,133 | 3,846 | $76K |
90 more codes
| 88141 | 1.9% | 3,644 | $71K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.7% | 9,363 | $65K |
| 36415 | Collection of venous blood by venipuncture | 1.7% | 21,578 | $64K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 9,311 | $57K |
| 80061 | Lipid panel | 1.4% | 5,229 | $54K |
| 86780 | 1.3% | 3,887 | $49K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.3% | 4,001 | $48K |
| 86762 | 1.2% | 3,372 | $45K | |
| 88304 | 1.1% | 3,273 | $41K | |
| 80053 | Comprehensive metabolic panel | 1.0% | 4,862 | $40K |
| 87340 | <1% | 3,530 | $34K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,488 | $32K |
| 80074 | <1% | 973 | $30K | |
| 86803 | <1% | 2,166 | $28K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 8,373 | $28K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,271 | $26K |
| 87077 | <1% | 3,503 | $26K | |
| 87186 | <1% | 3,140 | $25K | |
| 84702 | <1% | 1,810 | $20K | |
| 86885 | <1% | 3,543 | $19K | |
| 84439 | <1% | 2,656 | $19K | |
| 85060 | <1% | 1,076 | $18K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 820 | $17K |
| 87070 | <1% | 1,890 | $15K | |
| 86787 | <1% | 1,203 | $13K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 271 | $13K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,489 | $13K |
| 88341 | <1% | 255 | $11K | |
| 86580 | <1% | 1,639 | $11K | |
| 86706 | <1% | 1,268 | $11K | |
| 85610 | <1% | 3,484 | $10K | |
| 86900 | <1% | 3,390 | $10K | |
| 86901 | <1% | 3,352 | $9K | |
| 88108 | <1% | 430 | $9K | |
| 81000 | <1% | 3,050 | $8K | |
| 85027 | <1% | 1,556 | $8K | |
| 87653 | <1% | 297 | $8K | |
| 87631 | <1% | 79 | $8K | |
| 87507 | <1% | 16 | $7K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 75 | $7K |
| 82150 | <1% | 1,165 | $6K | |
| 82951 | <1% | 519 | $6K | |
| 82728 | <1% | 508 | $6K | |
| 82607 | <1% | 435 | $5K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 12 | $5K |
| 88300 | <1% | 862 | $5K | |
| 88311 | <1% | 586 | $5K | |
| 88173 | <1% | 69 | $4K | |
| 84481 | <1% | 296 | $4K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 27 | $4K |
| 80076 | <1% | 539 | $4K | |
| 85652 | <1% | 1,412 | $3K | |
| 82570 | <1% | 507 | $2K | |
| 88142 | <1% | 118 | $2K | |
| 83789 | <1% | 121 | $2K | |
| 84156 | <1% | 540 | $2K | |
| 85018 | <1% | 887 | $2K | |
| 85651 | <1% | 585 | $2K | |
| 86704 | <1% | 139 | $2K | |
| 82670 | <1% | 67 | $2K | |
| 84403 | <1% | 73 | $1K | |
| 80164 | <1% | 166 | $1K | |
| 83540 | <1% | 237 | $1K | |
| 88312 | <1% | 29 | $1K | |
| 82947 | <1% | 301 | $989.24 | |
| 85048 | <1% | 719 | $844.59 | |
| 88331 | <1% | 13 | $710.01 | |
| 88112 | <1% | 28 | $603.82 | |
| 88333 | <1% | 13 | $584.06 | |
| 85007 | <1% | 464 | $538.61 | |
| 82950 | <1% | 112 | $495.02 | |
| 86140 | <1% | 129 | $483.00 | |
| 82565 | <1% | 252 | $480.05 | |
| 83001 | <1% | 28 | $445.25 | |
| 84460 | <1% | 161 | $432.95 | |
| 83735 | <1% | 95 | $369.54 | |
| 84450 | <1% | 148 | $355.90 | |
| 87625 | <1% | 60 | $247.80 | |
| 80178 | <1% | 62 | $247.45 | |
| 83550 | <1% | 38 | $228.00 | |
| 84520 | <1% | 98 | $197.30 | |
| 82105 | <1% | 13 | $180.28 | |
| 86376 | <1% | 12 | $165.84 | |
| 87081 | <1% | 17 | $114.60 | |
| 88302 | <1% | 13 | $92.18 | |
| 84703 | <1% | 15 | $90.08 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 64 | $69.09 |
| 84132 | <1% | 31 | $54.60 | |
| 82310 | <1% | 12 | $12.10 | |
| 84100 | <1% | 12 | $11.12 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWOLTMAN, MICHAEL (PRESIDENT)